Abstract:Abstract The human epidermal growth factor receptor (EGFR) is expressed at high levels in at least 20% of breast cancers overall, but in 60-70% of patients with triple-negative breast cancer (TNBC), which makes EGFR a potential treatment target. Herein we developed a novel therapy for TNBC that utilizes anti-EGFR monoclonal antibody (mAb)-conjugated nanodiamonds (NDs) to specifically deliver paclitaxel (PTX) to breast cancer cells over-expressing EGFR. NDs, 2-8 nm diameter carbon nanoparticles, have recently emerged as promising drug carriers. In this study, we have synthesized a versatile ND construct that incorporates anti-EGFR mAb, fluorescent imaging agent and paclitaxel for multimodal imaging, targeting and treatment of TNBC. Sulfo-LC-SPDP was attached on to an aminated ND surface (ND-NH2), yielding sulfhydryl-reactive NDs (ND-SPDP). Thiolated paclitaxel-oligonucleotide (PTX-DNA) conjugates and thiolated mAbs were then simultaneously attached to ND-SPDPs, forming PTX-DNA/mAb@NDs. For the PTX-DNA conjugate, a fluorescein-labeled dT-nucleotide was inserted within the thiolated 20-mer poly-dT strand for cellular imaging and PTX loading quantification. The resultant nanoparticles could form highly stable suspensions in aqueous solutions. Dithiothreitol treatment detaches PTX-DNA and thiolated mAbs from the ND surface. About 2.2 ± 0.4 nmol of PTX and 53.5 ± 2.1 µg of mAb were loaded on per mg of PTX-DNA/mAb@NDs, while 3.1 ± 0.7 nmol of PTX for per mg of PTX-DNA@NDs. The targeting capacity of PTX-DNA/mAb@NDs was tested through flow cytometry analysis and confocal microscopy within 2 breast cancer cells of contrasting EGFR expression. Internalization of PTX-DNA@NDs and PTX-DNA/mAb@NDs was nearly equivalent within basal EGFR expressing MCF7 cells. However, when EGFR-overexpressing MDA-MB-231 cells were treated with PTX-DNA/mAb@NDs, there was a nearly 150% enhancement in the fluorescence signal as compared to that of PTX-DNA@NDs. Internalization of anti-EGFR-conjugated NDs within MDA-MB-231 cells was competitively inhibited by the addition of EGF. MTT assays were performed comparing free PTX with untargeted and targeted versions of PTX-DNA@NDs at equivalent PTX dosages in both cells. Enhanced cytotoxicity was observed in escalating-dose studies after 48 h treatment of PTX-DNA@NDs and PTX-DNA/mAb@NDs across all concentrations. Within MDA-MB-231 cells, anti-EGFR linked conjugates had an IC50 value of 43.8 nM, a nearly two-fold increase in efficacy compared to untargeted conjugates (83.3 nM). The data suggests that targeting through the mAb moiety increases specificity and internalization, which subsequently enhances therapeutic activity. Intravenous injection of NDs (up to 1.2 mg) didn't induce any toxicity and systemic immune response in mice, attesting to NDs as a biocompatible nanocarrier platform. In vivo efficacy of PTX-DNA/mAb@NDs will be further investigated in tumor-bearing mice. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1962. doi:1538-7445.AM2012-1962

Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells

Abstract 367: Nano-immunotherapy in TNBC: Aptamer-based nanoparticles for PD-L1 siRNA delivery to cancer cells

Lipid-Based Nanoparticles Fused with Natural Killer Cell Plasma Membrane Proteins for Triple-Negative Breast Cancer Therapy

Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release

TNA‐Mediated Antisense Strategy to Knockdown Akt Genes for Triple‐Negative Breast Cancer Therapy

A Therapeutic Pretargeting Strategy for Triple-Negative Breast Cancer Based on a Bioorthogonal Reaction and a Self-Assembled Peptide

A Therapeutic Pretargeting Strategy for Triple‐Negative Breast Cancer Based on a Bioorthogonal Reaction and a Self‐Assembled Peptide

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer

Abstract 1962: Engineering of EGFR-targeted Nanoparticles for Triple Negative Breast Cancer Therapy

Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy

Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer

Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer

Aptamer-Based Strategies to Boost Immunotherapy in TNBC

Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody

Nanobody‐Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy

Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

Microneedles‐Mediated Intradermal Delivery of Paclitaxel/anti‐PD‐1 for Efficient and Safe Triple‐Negative Breast Cancer Therapy

Abstract 2708: Nano-immunotherapy: efficacy of nanoconjugate QN-247 in a triple negative breast cancer (TNBC) mouse model

Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells

Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple-Negative Breast Cancer

Antiangiogenic Nanomodulator Enhances Immune Response in Triple Negative Breast Cancer by Synergism of Photothermal Therapy and Transforming Growth Factor-β Blockade